Madri­gal's $600M of­fer­ing; PureTech to re­turn $100M to share­hold­ers

Plus, news about Out­look Ther­a­peu­tics, Geron, Fate Ther­a­peu­tics, En­liv­en Ther­a­peu­tics, See­los and Por­tal Biotech­nolo­gies:

Madri­gal Phar­ma­ceu­ti­cals’s $600M of­fer­ing: The com­pa­ny is rais­ing mon­ey to boost the launch of its land­mark NASH drug Rezd­if­fra. It priced 750,000 shares at $260 apiece, with a goal to bring in $600 mil­lion. That’s $100 mil­lion more than the com­pa­ny ini­tial­ly pen­ciled in when it an­nounced the pro­posed of­fer­ing on Mon­day. Rezd­if­fra, al­so known as resme­tirom, is the first ap­proved drug for NASH, a liv­er dis­ease now of­ten re­ferred to as meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis. — Nicole De­Feud­is

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER